News | News By Subject | News by Disease News By Date | Search News

Psoriatic Arthritis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Pfizer (PFE)'s Xeljanz Successful in Second Phase III Psoriatic Arthritis Study     6/7/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs     3/8/2016
Novartis AG (NVS) Wins Two New FDA Approvals for Cosentyx     1/19/2016
Amgen (AMGN) Dumps AstraZeneca PLC (AZN) Pact After Patients Developed Suicidal Thoughts     5/27/2015
Eli Lilly (LLY)'s Ixekizumab Succeeds in Late-Stage Study, Meets Primary Endpoint     4/22/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Analyst: Novartis AG (NVS), Celgene (CELG) Might Go Toe-to-Toe Over Psoriasis Drugs     9/26/2014
Celgene Corporation (CELG) Wins FDA Approval For Pill To Treat Psoriatic Arthritis     3/25/2014
Celgene Corporation (CELG) Arthritis Drug Appears Effective, Safe After One Year: Study     10/28/2013
Health Canada Approves Centocor Ortho Biotech Inc. and Schering-Plough Corporation (SGP)'s SIMPONI(TM) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis; First World Regulatory Approval for SIMPONI     4/14/2009
Centocor, Inc. (JNJ) Submits Application to FDA (JOBS) Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis     6/27/2008
FDA Expands Centocor, Inc. (JNJ)'s REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown To Inhibit Joint Damage And Improve Physical Function     8/14/2006
Biogen Idec, Inc. (Massachusetts) (BIIB) Promising AMEVIVE(R) Phase II Psoriatic Arthritis Data Presented At American College of Rheumatology Meeting     11/15/2005
Abbott Laboratories' (ABT) Humira Gets Additional OK For Psoriatic Arthritis     10/4/2005

News from Around the Web

Press Releases
Janssen R&D Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial     11/15/2016
Pfizer (PFE) Announces Results From Phase III OPAL Clinical Development Program Investigating XELJANZ (Tofacitinib Citrate) For Psoriatic Arthritis     11/15/2016
Celgene (CELG) Release: Data On Early Onset Of Efficacy For Oral Otezla (Apremilast) In Active Psoriatic Arthritis Presented At American College of Rheumatology     11/14/2016
Pfizer (PFE) To Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis And Psoriatic Arthritis     11/7/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101)     6/7/2016
AbbVie (ABBV)'s Leadership In Gastroenterology Showcased At Digestive Disease Week With New HUMIRA (Adalimumab) Long-Term, Real-World Research And Promising Anti-IL-23 Antibody Late-Breaking Data     5/19/2016
New Novartis AG (NVS) Data Show Cosentyx Demonstrated Sustained Superiority In Skin Clearance (PASI 90) Versus Stelara At Week 52     3/7/2016
Approximately 80% Of Psoriatic Arthritis Patients Treated With Cosentyx Saw No Progression Of Joint Damage As Shown In Novartis Pharmaceuticals Corporation (NVS) New Two-Year Observational Data     11/9/2015
Eli Lilly (LLY) Release: Patients Show Significant Improvement In Signs And Symptoms Of Psoriatic Arthritis, Less Progression Of Structural Joint Damage When Treated With Ixekizumab For 24 Weeks     11/9/2015
Janssen Biotech Inc. (JNJ) Data Presentations At American College of Rheumatology Meeting Showcase Commitment To Rheumatologic Diseases     11/4/2015
AbbVie (ABBV) Demonstrates Leadership In Dermatology With 26 Abstracts At The European Academy Of Dermatology And Venereology Congress     10/5/2015
Novartis AG (NVS) Announces The New England Journal of Medicine Publication Of secukinumab Phase III Data Confirming Significant Efficacy In Patients With Psoriatic Arthritis     10/1/2015
Eli Lilly (LLY)'s Ixekizumab Met Primary Endpoint In A Phase 3 Study Investigating The Treatment Of Psoriatic Arthritis     4/20/2015
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Approved By The European Commission For The Treatment Of Both Patients With Psoriasis And Psoriatic Arthritis     1/16/2015
EULAR: One Third Of Psoriatic Arthritis Patients Are Not Receiving Optimal Dosing Of Adalimumab     6/11/2014

//-->